Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.
about
Medical healthcare use in Parkinson's disease: survey in a cohort of ambulatory patients in ItalySpontaneous locomotor activity and L-DOPA-induced dyskinesia are not linked in 6-OHDA parkinsonian rats.Levodopa/benserazide microsphere (LBM) prevents L-dopa induced dyskinesia by inactivation of the DR1/PKA/P-tau pathway in 6-OHDA-lesioned Parkinson's rats.Do neurologists in Germany adhere to the national Parkinson's disease guideline?A novel quality of life instrument for deep brain stimulation in movement disordersLong-Term Treatment with Extended-Release Carbidopa-Levodopa (IPX066) in Early and Advanced Parkinson's Disease: A 9-Month Open-Label Extension Trial.Update on apomorphine for the rapid treatment of hypomobility ("off") episodes in Parkinson's disease.Depression in Parkinson's disease: health risks, etiology, and treatment options.Meta-analysis of longitudinal studies.Constant dopaminergic stimulation by transdermal delivery of dopaminergic drugs: a new treatment paradigm in Parkinson's disease.Effects and molecular mechanism of chitosan-coated levodopa nanoliposomes on behavior of dyskinesia rats.Costs of Parkinson's disease in a privately insured population.Assessing self-awareness of dyskinesias in Parkinson's disease through movie materials.The use of decision-analytic models in Parkinson's disease: a systematic review and critical appraisal.Patient diaries as a clinical endpoint in Parkinson's disease clinical trials.Optimizing levodopa therapy to treat wearing-off symptoms in Parkinson's disease: focus on levodopa/carbidopa/entacapone.Application of the concept of continuous dopaminergic stimulation for the management of Parkinson's disease.Estimating the direct and indirect costs associated with Parkinson's disease.A clinical view on the development of technology-based tools in managing Parkinson's disease.Continuous levodopa for advanced Parkinson's disease.Behind the mask : a study on the clinical course, psychopathology and impact on quality of life in idiopathic Parkinson's disease.Probabilistic sensitivity analysis for evaluating cost-utility of entacapone for Parkinson's disease.Quality of life in relation to mood, coping strategies, and dyskinesia in Parkinson's disease.Trial of dextromethorphan/quinidine to treat levodopa-induced dyskinesia in Parkinson's disease.Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).Evaluation of the Parkinson's KinetiGraph in monitoring and managing Parkinson's disease.Real life cost and quality of life associated with continuous intraduodenal levodopa infusion compared with oral treatment in Parkinson patients.Economic burden associated with Parkinson's disease on elderly Medicare beneficiaries.Cost-utility model of rasagiline in the treatment of advanced Parkinson's disease in Finland.Viewpoint and practical recommendations from a movement disorder specialist panel on objective measurement in the clinical management of Parkinson's disease.
P2860
Q24793543-FA4C3B9D-CBB1-44C9-81E9-CE530AF6655EQ34279877-21451138-CE7A-43C6-BC85-E4ADE94C0EF5Q34708186-8FC40F0C-00B2-4F05-98A5-EC6205DEA1E8Q34879044-C85AFDC4-4CE9-4791-80C6-0B4BC6DCAC9AQ35475745-8ED94B32-15A0-4AA5-A18C-A43A6FFE95B0Q36013084-7B4ABBC8-5E85-4EA5-9AC1-99D901206B60Q36484966-166A94A7-215F-46D9-BDCA-4A3E9EE1F071Q36836774-813AFDAB-BF8A-45E1-9734-15851E7FB189Q36974026-553494C3-3026-4BDA-9859-E818F1AC4735Q37016310-D5BF414C-1559-46F1-9FDC-B89F23E5CB65Q37064567-C98BA591-90D0-494C-BCB8-485FE70584FAQ37132304-A6789FA6-C562-49D0-BCFB-17E1E37F0884Q37271592-3FD29E2A-83B3-46B8-B2FF-DE1BFF645EB2Q37891050-311B3DCA-EC98-45C5-A0EE-26D59AA3EB81Q37954392-ECB50CE0-60DC-4D82-998F-F6E2A34B29F2Q37979869-4015CB06-7FA5-44A2-A89F-A8F1F3417642Q38091388-1F412602-EDAB-45DE-9BD6-DC026BB00040Q38618871-B156CAAC-D26A-4AA9-902E-1EE1DD8A29E9Q38858508-D033427F-C225-4DAB-95C2-76BA23EC22AFQ41825026-34F76D7B-68FA-4FD2-B20F-188E68C35018Q42413314-0D92A474-498B-4986-A984-0AAD3882F3C7Q43266423-3F98A771-067E-47A5-84E6-C4B385D32D48Q45352049-A15BAB90-803B-4C56-8A47-095DB4AA8E0EQ46280394-E79D8135-F4EF-4C1D-ABAB-B403456A5557Q46641045-E4240431-A5D0-49DB-B33B-E004A531D7B5Q47557053-5096D160-A3D1-4EF4-9A8D-EC1AB363647DQ48064134-D14F2AE6-E9F0-4235-89BA-4DC1D8A36756Q50770517-0753078C-6727-43ED-AB52-3D63F0822ECBQ53930312-7FF4B352-1FC7-4F61-A1E6-0B7D951714F4Q54958506-82C835BB-3098-4DFE-94AE-65C2E63DC137
P2860
Health-related quality of life and healthcare utilisation in patients with Parkinson's disease: impact of motor fluctuations and dyskinesias.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Health-related quality of life ...... fluctuations and dyskinesias.
@ast
Health-related quality of life ...... fluctuations and dyskinesias.
@en
Health-related quality of life ...... fluctuations and dyskinesias.
@nl
type
label
Health-related quality of life ...... fluctuations and dyskinesias.
@ast
Health-related quality of life ...... fluctuations and dyskinesias.
@en
Health-related quality of life ...... fluctuations and dyskinesias.
@nl
prefLabel
Health-related quality of life ...... fluctuations and dyskinesias.
@ast
Health-related quality of life ...... fluctuations and dyskinesias.
@en
Health-related quality of life ...... fluctuations and dyskinesias.
@nl
P921
P1433
P1476
Health-related quality of life ...... fluctuations and dyskinesias.
@en
P2093
P304
P356
10.2165/00019053-200119100-00004
P577
2001-01-01T00:00:00Z
P6179
1038745039